AtaiBeckley (ATAI) Share-based Compensation (2020 - 2026)
AtaiBeckley (ATAI) posted Share-based Compensation of $21.4 million for Q3 2025, up 921.97% sequentially from $2.1 million in Q2 2025, and up 4180.0% YoY from $500000.0 in Q3 2024.
Analysis
AtaiBeckley (ATAI) Share-based Compensation (2020 - 2026) Analysis & Trends
AtaiBeckley's Share-based Compensation history runs 2 years deep, the most recent figure standing at $50.8 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 1414.16% year-over-year to $50.8 million; the TTM figure through Mar 2026 stood at $50.8 million (changed N/A YoY), while the FY2025 annual figure was $14.2 million, down 44.24% from the prior year.
- Share-based Compensation improved to $21.4 million in Q3 2025 per ATAI's latest filing, from $2.1 million in the prior quarter.
- The five-year high for Share-based Compensation was $50.8 million in Q1 2026, with the low at $3.4 million in Q1 2025.
- A 5-year average of $6.5 million and a median of $6.0 million in 2024 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2022 and 2024: Share-based Compensation slumped 99.38% in 2022, then soared 5750.47% in 2024.
- Over 5 years, Share-based Compensation stood at $13.4 million in 2021, then declined by 9.39% to $12.1 million in 2022, then plunged by 39.83% to $7.3 million in 2023, then rose by 15.02% to $8.4 million in 2024, then soared by 154.7% to $21.4 million in 2025.
- According to Business Quant data, Share-based Compensation over the past three periods registered $21.4 million, $2.1 million, and $8.4 million for Q3 2025, Q2 2025, and Q4 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | 120.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | 277.20 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 137.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | - |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 10 | AtaiBeckley | 1.61 Bn | 1.61 Bn | - | 23.89 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 33.53 Mn |
| Mar 31, 2026 | 34.32 Mn |
| Dec 31, 2025 | 6.92 Mn |
| Sep 30, 2025 | 23.89 Mn |
| Jun 30, 2025 | 27.20 Mn |
| Jun 30, 2025 | 2.69 Mn |
| Mar 31, 2025 | 3.36 Mn |
| Mar 31, 2025 | 24.14 Mn |
| Dec 31, 2024 | 6.92 Mn |
| Dec 31, 2024 | 8.40 Mn |
| Sep 30, 2024 | 500,000.00 |
| Jun 30, 2024 | 6.28 Mn |
| Mar 31, 2024 | 22.86 Mn |
| Dec 31, 2023 | 7.31 Mn |
| Sep 30, 2023 | 18.75 Mn |
| Jun 30, 2023 | 20.84 Mn |
| Mar 31, 2023 | 19.09 Mn |
| Dec 31, 2022 | 12.14 Mn |
| Sep 30, 2022 | 18.93 Mn |
| Jun 30, 2022 | 21.04 Mn |